Summary: In late March, the U.S. Supreme Court will hear arguments regarding the constitutionality of the recently passed healthcare legislation. In this call, we discuss our views on why healthcare reform was enacted, the economics surrounding the sector, and what impact the Supreme Court ruling may have for investors. Please join Lazard's principal healthcare industry specialists, Ross Seiden, Vice President, Research Analyst and Rhett Brown, Director, Research Analyst, as they look beyond the headlines and provide insight around healthcare reform and its implications for long-term investing. Featured Speakers: H. Ross Seiden Vice President, Research Analyst Ross Seiden is a Vice President and Research Analyst on the healthcare sector team. He began working in the investment field in 2006. Prior to joining Lazard in 2010, Ross was with Credit Suisse where he started as an Equity Research Analyst and later became an Equity Research Associate covering multinational banks and capital markets firms. Ross has a BBA in Finance and Accounting from the Ross School of Business at the University of Michigan. He holds FINRA Series 7, 63, 86, and 87 licenses. Rhett E. Brown, CFA Director, Research Analyst Rhett Brown is a Director and Research Analyst on the healthcare sector team. He began working in the investment field in 1996. Prior to joining Lazard in 2005, he was an Assistant Vice President in Equity Research at Deutsche Bank Securities and an Equity Research Associate at Volpe Brown Whelan & Company. Previously, Rhett was an Account Representative at Amersham Life Science, a Marketing Specialist in the Applied Biosystems Division of Perkin Elmer and a Research Assistant at Immulogic Pharmaceutical Corporation. Rhett has an MBA (Hons) in Finance from the Wharton School, University of Pennsylvania and a BS (Hons) in Biological Sciences from Stanford University. He is a member of the Security Analysts of San Francisco.
